PAHO provides Latin America and the Caribbean with new access to HIV drugs

The Pan Amer­i­can Health Or­ga­ni­za­tion (PA­HO) says it is pro­vi­did­ng new op­por­tu­ni­ties for Latin Amer­i­ca and the Caribbean (LAC) to ac­cess lenaca­pavir as part of the pre­ven­ta­tive med­i­cine to curb the spread of HIV through­out the re­gion.

PA­HO said that the med­ica­tion will be made avail­able through its Re­gion­al Re­volv­ing Funds, un­der an agree­ment with Gilead Sci­ences and that the ini­tia­tive will make the long-act­ing HIV pre­ven­tion med­i­cine avail­able to 14 coun­tries.

“The agree­ment be­tween Gilead and PA­HO re­flects our shared com­mit­ment to help coun­tries move as quick­ly as pos­si­ble from sci­en­tif­ic in­no­va­tion to re­al-world ac­cess to HIV pre­ven­tion and pub­lic health im­pact,” said Jo­han­na Merci­er, Chief Com­mer­cial & Cor­po­rate Af­fairs Of­fi­cer, Gilead Sci­ences.